Table 1. Patient characteristics at the time of primary diagnosis.
| Total | 79 |
|---|---|
| Age | median 60 years, (26–86) |
| FIGO stage | |
| I–II | 21 (26%) |
| III | 48 (61%) |
| IV | 10 (13%) |
| Nodal status | |
| No | 32 (40,5%) |
| N1 | 32 (40,5%) |
| Nx | 10 (19%) |
| Grading | |
| I–II | 44 (56%) |
| III | 33 (42%) |
| Unknown | 2 (2%) |
| Residual tumor | |
| Macroscopic | |
| Complete resection | 49 (62%) |
| Any residual tumor | 30 (38%) |
| Histologic type | |
| Serous | 47 (60%) |
| Mucinous | 9 (11%) |
| Other | 23 (29%) |
| DTC | |
| Before therapy | 33 (42%) |
| After therapy | 32 (41%) |
| Survival | |
| PFS1 | median 15 months, (4–87 months) |
| OS2 | median 62 months, (10–128 months) |
| Alive | 44 (56%) |
| Dead | 33 (42%) |
| Unknown | 2 (2%) |
| Recurrence | |
| No relapse | 25 (32%) |
| Relapse | 53 (67%) |
| Unknown | 1 (1%) |
| Platinum resistance | |
| Platinum sensitive | 60 (76%) |
| Platinum resistant | 19 (24%) |
1
PFS: progression-free survival
2
OS: overall survival.